The international and domestic research trends of targeted therapy in bladder cancer: a bibliometric analysis of the past three decades
By
Yijin Pan
Yu Sun
Binbin Jiao
Yinqiang Zhang
Guan Zhang
May 25, 2026
Clinical Scorecard: Global and National Research Trends in Targeted Therapy for Bladder Cancer: A Bibliometric Review Over the Last Thirty Years
At a Glance
Category Detail
Condition Key Mechanisms Targeted therapy aims to inhibit tumor growth by specifically targeting key molecular sites within cancer cells. [Source needed] Target Population Care Setting
Key Highlights
The annual publication volume on targeted therapy for bladder cancer has shown an upward trend over the past three decades. The USA and Europe dominate the research landscape in targeted therapy for bladder cancer. Recent FDA approvals include erdafitinib and enfortumab vedotin for bladder cancer treatment. Research hotspots include drug management for metastatic bladder cancer and overcoming drug resistance. Guideline-Based Recommendations
Diagnosis
Management
Targeted therapies such as pan-FGFR tyrosine kinase inhibitors and antibody-drug conjugates are recommended. [Source needed] Monitoring & Follow-up
Risks
Patient & Prescribing Data
Bladder cancer patients, particularly those at high risk for recurrence.
Targeted therapies are developed based on the molecular characteristics of bladder cancer.
Clinical Best Practices
Related Resources & Content
